证券代码：600671 证券简称：天目药业 公告编号：2026-002 杭州天目山药业股份有限公司 关于公司及子公司 2025 年度向银行等金融机构申请 综合授信提供担保事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 16,422.37 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 313.50 | | 特别风险提示 | □担保金额（含本次）超过上市公司最近一 | | | 期经审计净资产 50% | | | ☑对外担保总额（含本次）超过上市公司最近 | | | 一期经审计净资产 100% | | | □对合并报表外单位担保总额（含本次）达 | | | 到或超过最近一期经审计净资产 30% | | | ☑本次对资产负债率超过70%的单位提供担保 | 1 担保对象及基本情况 被担保人名称 本次担保金额 实际为其提供的 担保 ...

2025年10月29日公司发布的三季报数据显示，前三季度公司共实现营业收入1.59亿元，同比增长 27.48%，实现净利润1420.88万元，同比增长484.48%。（数据宝） 天目药业1月22日交易公开信息 天目药业(600671)今日下跌9.69%，全天换手率11.11%，成交额2.80亿元，振幅13.66%。龙虎榜数据显 示，营业部席位合计净卖出2092.58万元。 上交所公开信息显示，当日该股因日跌幅偏离值达-9.83%上榜，营业部席位合计净卖出2092.58万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交9615.28万元，其中，买入成交额为 3761.35万元，卖出成交额为5853.93万元，合计净卖出2092.58万元。 具体来看，第一大买入营业部及卖出营业部均为高盛(中国)证券有限责任公司上海浦东新区世纪大道证 券营业部，买入金额为955.44万元，卖出金额为1522.57万元。 资金流向方面，今日该股主力资金净流出1792.06万元，其中，特大单净流出1121.35万元，大单资金净 流出670.70万元。近5日主力资金净流入2136.26万元。 | 买/ | 会员营业部名称 ...

格隆汇1月22日｜天目药业今日跌9.69%，龙虎榜数据显示，上榜营业部席位全天成交9615.28万元，占 当日总成交金额比例为34.31%。其中，买入金额为3761.35万元，卖出金额为5853.93万元，合计净卖出 2092.58万元。具体来看，高盛证券有限责任公司上海浦东新区世纪大道证券营业部、中信证券股份有 限公司上海分公司分别买入955.44万元、844.89万元；高盛证券有限责任公司上海浦东新区世纪大道证 券营业部、中信证券股份有限公司上海分公司分别卖出1522.57万元、1300.53万元。 ...

证券之星消息，1月22日中药板块较上一交易日下跌0.13%，天目药业领跌。当日上证指数报收于 4122.58，上涨0.14%。深证成指报收于14327.05，上涨0.5%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | --- | | 300391 | *ST长药 | 0.77 | 20.31% | | 32.78万 | | 2516.12万 | | 603896 | 寿仙谷 | 22.28 | 3.92% | | 6.29万 | | 1.39亿 | | 002864 | 盘龙药业 | 37.30 | 3.32% | | 8.06万 | | 3.00亿 | | 661509 | ST葫芦娃 | 7.08 | 2.76% | | 4.46万 | | 3125.21万 | | 603139 | 康惠股份 | 22.23 | 2.44% | | 2.62万 | | 5796.86万 | | 600222 | 太龙药业 | 6.68 | 2.14% | | 17 ...

公司股票于 2026 年 1 月 19 日、1 月 20 日和 1 月 21 日连续三个交易日内收 盘价格涨幅偏离值累计达到 20%。根据《上海证券交易所交易规则》等相关规定， 属于股票交易异常波动的情形。 杭州天目山药业股份有限公司 关于股票交易异常波动公告 证券代码：600671 证券简称：天目药业 公告编号：2026-001 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、股票交易异常波动的具体情况 （四）其他股价敏感信息 二、公司关注并核实相关情况 针对公司股票交易异常波动，公司对有关事项进行了自查，并书面函证了公 司控股股东，现将有关情况说明如下： （一）生产经营情况 经公司自查，公司目前生产经营活动正常，内部生产经营秩序正常，市场环 境及行业政策未发生重大调整。 （二）重大事项情况 1 杭州天目山药业股份有限公司（以下简称"公司"）股票于 2026 年 1 月 19 日、1 月 20 日和 1 月 21 日连续三个交易日内收盘价格涨幅偏离值累 计超过 20%，属于《上海证券交易所交易规则》规定的 ...

Core Viewpoint - The company announced that its stock experienced an abnormal fluctuation, with a cumulative closing price increase of 20% over three consecutive trading days from January 19 to January 21, 2026 [1] Group 1 - The company conducted a self-examination and verified with its controlling shareholder, Huazhe Holdings, confirming that its production and operations are normal [1] - There are no undisclosed significant information or media reports that could have a substantial impact on the stock price [1] - During the period of abnormal fluctuation, the controlling shareholder, directors, and executives did not engage in any buying or selling of the company's stock [1] Group 2 - The company reminds investors to be cautious of trading risks [1]

Group 1 - The Chinese medicine sector saw a rise of 0.54% on January 20, with *ST Changyao leading the gains [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] - Notable gainers in the Chinese medicine sector included *ST Changyao with a closing price of 0.53, up 20.45%, and ST Xiangxue with a closing price of 9.72, up 7.05% [1] Group 2 - The Chinese medicine sector experienced a net outflow of 23.25 million yuan from major funds, while retail investors saw a net inflow of 20.95 million yuan [2] - The top stocks by net inflow from retail investors included *ST Changyao and ST Xiangxue, with retail inflows of 2.20 million yuan and 4.16 million yuan respectively [3] - Major funds showed a significant net outflow in stocks like Zhongsheng Pharmaceutical and Yiling Pharmaceutical, with net outflows of 10.68 million yuan and 5.57 million yuan respectively [3]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300391 | *ST长药 | 0.44 | -18.52% | 80.35万 | 3755.51万 | | 002317 | 众生药业 | 21.67 | -1.95% | 79.70万 | 17.45亿 | | 002424 | ST百灵 | 4.27 | -1.39% | 28.70万 | 1.24亿 | | 300147 | ST香雪 | 9.08 | -1.30% | 7.84万 | 7117.68万 | | 920266 | 生物谷 | 9.36 | -1.27% | 1.07万 | 1002.85万 | | 300158 | 振东制药 | 6.08 | -0.65% | 17.81万 | 1.09亿 | | 600422 | 昆药集团 | 12.82 | -0.62% | 6.94万 | 8895.05万 | | 600436 | 片仔瘦 | 167.82 | -0.52% | 2.31万 | 3.87亿 | | 002349 | ...

证券日报网讯1月16日，天目药业（600671）在互动平台回答投资者提问时表示，截至2026年1月9日， 公司股东人数为9687户。 ...

Group 1 - The core viewpoint of the news is that Tianmu Pharmaceutical has shown a positive stock performance with a 3.52% increase year-to-date and a significant rise in revenue and net profit for the first nine months of 2025 [1][2] Group 2 - As of January 15, Tianmu Pharmaceutical's stock price was 17.92 CNY per share, with a market capitalization of 2.182 billion CNY and a trading volume of 21.8786 million CNY [1] - The company experienced a net inflow of main funds amounting to 299,600 CNY, with large orders accounting for 5.87% of total purchases [1] - The company's revenue for the first nine months of 2025 reached 159 million CNY, reflecting a year-on-year growth of 27.48%, while the net profit attributable to shareholders was 14.21 million CNY, up 484.48% year-on-year [2] Group 3 - Tianmu Pharmaceutical's main business revenue composition includes health products (48.01%), circulation goods (23.21%), raw materials (15.98%), traditional Chinese medicine (11.47%), Western medicine (0.89%), training (0.32%), and others (0.12%) [1] - The company has not distributed any dividends in the last three years, with a total payout of 59.6313 million CNY since its A-share listing [3]